GlassScriptPhysician profile
Paige Malick
NPI 1083213102
$4,984.34
in general payments reported to CMS, 2019-2025
27 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $212 · 2023: $1,569 · 2024: $1,924 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,772.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,068.52 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $888.71 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $514.41 | 2023-2025 | |
| Lilly USA, LLC | $342.92 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Glaxosmithkline, LLC. | $330.13 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.07 | 2023-2025 | Xifaxan |
| Amgen INC. | $250.49 | 2023-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $234.56 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.27 | 2023-2024 | Caplyta |
| Pfizer INC. | $149.68 | 2022-2025 | |
| Abbott Laboratories | $145.84 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $106.42 | 2022 | |
| Corcept Therapeutics | $91.25 | 2022-2023 | Korlym |
| Exact Sciences Corporation | $67.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $45.14 | 2024 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.99 | 2022-2023 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2023-2024 | Jardiance |
| Genzyme Corporation | $28.31 | 2025 | |
| Seqirus USA INC | $26.50 | 2025 | Fluad, Flucelvax |
| Bayer Healthcare Pharmaceuticals INC. | $21.62 | 2025 | |
| Aimmune Therapeutics, INC. | $21.61 | 2025 | Zenpep |
| Intra-Sana Laboratories | $19.11 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Hikma Pharmaceuticals USA | $18.17 | 2025 | Ryaltris |
| Optinose US, INC. | $18.08 | 2023 | |
| Dexcom, INC. | $16.29 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $15.43 | 2024 | Yupelri |
| Currax Pharmaceuticals LLC | $13.91 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Malick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.